The KRT20 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 786-O human cell line, engineered to disrupt the KRT20 gene. This heterogeneous pool provides a loss-of-function model for studying keratin 20 biology without clonal selection bias, suitable for assays requiring population-level analysis of gene disruption.
The 786-O parental line is a clear cell renal cell carcinoma epithelial cell line established from a primary kidney adenocarcinoma of a 58-year-old male. These cells are VHL-deficient, leading to constitutive HIF pathway activation, and serve as a widely used model for renal cell carcinoma research, characterized by dysregulated angiogenesis and metabolic alterations.
KRT20 encodes keratin 20, a type I intermediate filament protein that obligately heterodimerizes with keratin 8 (KRT8) to assemble into the epithelial intermediate filament network. Its expression is transcriptionally activated by CDX2 and modulated by Notch signaling, retinoic acid, and GATA factors. KRT20 interacts with desmosomal proteins desmoplakin and plakoglobin, and associates with cytoskeletal adaptors to maintain epithelial barrier function and structural integrity. The KRT20/KRT8 heterodimers integrate into desmosomes and hemidesmosomes, anchoring the cytoskeleton to intercellular junctions and extracellular matrix, thus participating in intermediate filament organization and epithelial differentiation.
In the VHL-deficient 786-O renal carcinoma context, KRT20 knockout allows dissection of epithelial differentiation programs against a background of HIF-driven oncogenic signaling. Despite low endogenous KRT20, disruption enables assessment of residual or inducible keratin 20 functions in cytoskeletal dynamics, migration, and epithelial-mesenchymal transition. This model helps elucidate mechanisms by which intermediate filament networks influence tumor cell behavior and may reveal vulnerabilities in VHL-deficient epithelial cancers.
Researchers can employ these polyclonal knockout cells for Western blot, immunofluorescence, and RT-qPCR confirmation of KRT20 depletion, co-immunoprecipitation with KRT8 to examine filament assembly, and functional assays such as migration and invasion studies. Applications include cancer biomarker identification, epithelial differentiation research, and drug screening in renal cell carcinoma. For detailed technical inquiries or custom cell line requests, please contact Ascent Research.
